89 Biggest Movers From Friday
Gainers
Revlon, Inc. (NYSE: REV) jumped 91.3% to close at $3.73 on Friday after the company filed for Chapter 11 bankruptcy.
Synlogic’s Return On Capital Employed Overview
Benzinga Pro data, Synlogic (NASDAQ:SYBX) reported Q1 sales of $224.00 thousand. Earnings fell to a loss of $15.70 million, resulting in a 4.03% decrease from last quarter.
Synlogic Announced Positive Opinion on Orphan Designation from the European Medicines Agency for SYNB1618 for the Treatment of Phenylketonuria
Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its proprietary approach to synthetic biology, today announced that the European Medicines Agency (EMA) issued a positive opinion on the Company's application for orphan designation for SY
Oppenheimer Maintains Outperform on Synlogic, Lowers Price Target to $6
Oppenheimer analyst Mark Breidenbach maintains Synlogic (NASDAQ:SYBX) with a Outperform and lowers the price target from $7 to $6.
Synlogic Q1 EPS $(0.22) Beats $(0.24) Estimate, Sales $224.00K Beat $190.00K Estimate
Synlogic (NASDAQ:SYBX) reported quarterly losses of $(0.22) per share which beat the analyst consensus estimate of $(0.24) by 8.33 percent. This is a 38.89 percent increase over losses of $(0.36) per share from the same
SVB Leerink Maintains Outperform on Synlogic, Lowers Price Target to $8
SVB Leerink analyst Joseph Schwartz maintains Synlogic (NASDAQ:SYBX) with a Outperform and lowers the price target from $11 to $8.
The Daily Biotech Pulse: AbbVie’s Rinvoq Gets Label Expansion, AstraZeneca COVID Antibody Cocktail Authorized By UK Regulator, Stealth Touts Positive Data
Here's a roundup of top developments in the biotech space over the last 24 hours:
Earnings Preview For Synlogic
Synlogic (NASDAQ:SYBX) is set to give its latest quarterly earnings report on Thursday, 2022-03-17. Here's what investors need to know before the announcement.
Analysts estimate that Synlogic will report an earnings per share (EPS) of $-0.26.
The Week Ahead In Biotech (March 13-19): Bristol-Myers Squibb’s Melanoma Drug Decision, Multiple Conference Presentations And Earnings Dominate Proceedings
Biotech stocks pulled back for a second week running, as the Ukraine war cast its cloud on the broader market. Dwindling earnings news flow and company-specific developments served as catalysts during the week.